Back to Agenda
Session 1: Patients are waiting: Health Authority regulators, WHO and Industry approaches to accelerate patients’ access to innovation
Session Chair(s)
Catherine Al Ashram
VP Regulatory Affairs & PV, Latin America MEA and Russia, Organon, Jordan
Jeffrey Kemprecos
CGA Director-Gulf, Glaxosmithkline, United Arab Emirates
Session 1: Patients are waiting: Health Authority Regulators, WHO and Industry approaches to accelerate patients’ access to innovation
Speaker(s)
Putting Reliance into Practice: WHO’s Activities on Regulatory Systems Strengthening
Samvel Azatyan, MD
Deputy Secretary-General, Council For International Organizations of Medical Sciences (CIOMS), Switzerland
The ICH perspective
Lenita Lindström, LLM
ICH Assembly Chair and Senior Expert, European Commission, European Commission, Belgium
Access to Innovative Medicines: Study Comparing Regulatory Timelines in 10 Countries in the Middle East & Africa
Mohamed Omar
Associate Director, IQVIA, Egypt
The Reliance Model Implementation in Practice: Examples from Jordan, Saudi Arabia and Egypt - Introduction
Inas Chehimi
Head Regulatory Affairs - Middle East & North Africa, Novartis Pharma Services AG, United Arab Emirates
The Reliance Model Implementation in Practice: Example from Egypt
Heba Nabil
Chair-Egypt RWG EFPR & Regulatory Sciences Director- Egypt & Sudan, Pfizer, Egypt
The Reliance Model Implementation in Practice: Example from Jordan
Wesal Al Haqish
Drug Directorate Director, Jordan Food and Drug Administration (JFDA), Jordan
The Reliance Model Implementation in Practice: Example from Saudi Arabia
Bandar Al Hammad, MPharm
Chief Pharmacist & Director of Veterinary Products Department, Saudi Food and Drug Authority (SFDA), Saudi Arabia
Have an account?